Investors Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading on Thursday. Stock traders acquired 19,524 call options on the stock. This is an increase of 30% compared to the typical volume of 15,030 call options.

Analysts Set New Price Targets

RXRX has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Morgan Stanley boosted their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Bank of America lowered their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Finally, Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $3.15 on Friday. The stock has a 50 day moving average price of $3.32 and a 200 day moving average price of $3.78. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -2.62 and a beta of 1.04. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. During the same period in the prior year, the company posted ($0.50) earnings per share. The firm’s quarterly revenue was down 56.8% compared to the same quarter last year. Research analysts predict that Recursion Pharmaceuticals will post -0.99 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total transaction of $110,400.00. Following the completion of the transaction, the director directly owned 6,169,863 shares of the company’s stock, valued at approximately $22,705,095.84. The trade was a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the transaction, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 125,930 shares of company stock valued at $435,942. 8.43% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently modified their holdings of the stock. International Assets Investment Management LLC purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth approximately $31,000. Allworth Financial LP raised its stake in shares of Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after purchasing an additional 4,403 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth approximately $41,000. IFP Advisors Inc raised its stake in shares of Recursion Pharmaceuticals by 81.5% during the third quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock worth $51,000 after purchasing an additional 4,650 shares during the last quarter. Finally, Savant Capital LLC purchased a new stake in shares of Recursion Pharmaceuticals during the third quarter worth approximately $54,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.